Nitric oxide modulates coronary autoregulation in the guinea pig.
A guinea pig heart Langendorff preparation was used in the present study to test the hypothesis that the coronary endothelium modulates coronary autoregulation through the production of nitric oxide (NO). Pacing at 250 beats per minute and venting the left ventricle to ensure that the hearts did no external work were performed in an attempt to reduce the metabolic stimulus to coronary vasomotion and keep it constant. We measured the responses of coronary flow and oxygen metabolism to stepwise changes of the perfusion pressure over the range between 18 and 85 mm Hg. The hearts exhibited autoregulation between 25 and 55 mm Hg and active vasodilation at perfusion pressures above that range. Perfusion with 100 microM NG-nitro-L-arginine (NNLA), an inhibitor of NO synthase, decreased coronary flow over the entire range of perfusion pressures and abolished active vasodilation over 65 mm Hg, thus widening the autoregulatory range. The administration of 200 microM L-arginine, but not D-arginine, reversed the action of NNLA. Inhibition of the cyclooxygenase pathway by 10 microM indomethacin did not affect autoregulation. Perfusion with 1 nM arginine vasopressin, a direct smooth muscle constrictor, lowered coronary flow rate to the same extent as NNLA at 55 mm Hg but did not prevent the pressure-dependent increase in flow above that pressure. These observations suggest that 1) the coronary endothelium actively modulates coronary autoregulation through the production of NO but not prostanoids, 2) mechanical stress (shear stress and/or stretching secondary to vasodilation) may be the stimulus to NO production, especially above the autoregulatory range, and 3) autoregulatory tone is likely to be myogenic in origin rather than mediated by extrinsic vasoconstrictors.
Ueeda
M
M
Department of Internal Medicine, University of South Florida, Tampa.
Silvia
S K
SK
Olsson
R A
RA
D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors; D000818:Animals; D003326:Coronary Circulation; D003331:Coronary Vessels / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000502:physiology; D006168:Guinea Pigs; D006706:Homeostasis; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D010101:Oxygen Consumption; D010477:Perfusion; D014667:Vasopressins / Q000494:pharmacology
D016861:Cyclooxygenase Inhibitors; D014667:Vasopressins; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases; D007213:Indomethacin